摘要：The influx of genetic science into biomedicine and research raises the question of whether predictive or diagnostic information derived from the molecular analysis of DNA merit distinctive legal consideration or policy treatment. The question arises in research, clinical care, and health policy settings. In research settings, investigators and Institutional Review Boards ("IRBs") must consider whether tissue samples containing DNA should be treated differently from other specimens that are not subject to molecular DNA analysis) In clinical care settings, physicians or genetic counselors must consider whether the use of DNAbased information carries wider obligations than the use of ordinary confidential medical information. 2 In health policy settings, insurers, legislators, and other regulators must consider whether information derived directly from the analysis of DNA should be treated differently from other medical information currently used in making decisions about insurance or employment
